VIA
AXSM icon

Virtus Investment Advisers’s Axsome Therapeutics AXSM Stock Holding History

Virtus Investment Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$963K Buy
5,698
+1,087
+24% +$188K 0.27% 144
2025
Q4 		$842K Buy
4,611
+428
+10% +$59.8K 0.23% 139
2025
Q3 		$508K Hold
4,183
– – 0.15% 205
2025
Q2 		$437K Buy
4,183
+377
+10% +$39.9K 0.15% 208
2025
Q1 		$444K Buy
+3,806
New +$434K 0.12% 203

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus Investment Advisers's AXSM Position: Q1 2026 in Review

Virtus Investment Advisers increased its Axsome Therapeutics (AXSM) stake by 24% in Q1 2026, buying an estimated $188K and bringing the position to 5,698 shares worth $963K. The position accounts for 0.27% of the portfolio, ranked #144.

Virtus Investment Advisers first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Virtus Investment Advisers held 5,698 shares of Axsome Therapeutics worth $963K as of Q1 2026.
  • Virtus Investment Advisers bought 1,087 Axsome Therapeutics shares in Q1 2026, an estimated $188K.
  • Axsome Therapeutics made up 0.27% of Virtus Investment Advisers's portfolio in Q1 2026, its #144 holding.
  • Virtus Investment Advisers first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.